BackScopus Biopharma Overview

Scopus Biopharma Long Term Debt

Latest long-term debt for SCPS: $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average

Loading

Scopus Biopharma Long Term Debt History

Loading

Scopus Biopharma vs. peers: Long Term Debt Comparison

Loading

Scopus Biopharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Scopus Biopharma (SCPS) FAQ

Scopus Biopharma (SCPS) currently reports a long-term debt of $0 as of June 2023. In the prior-year period, the figure was $0. Use the charts on this page to explore Scopus Biopharma's long-term debt history and peer comparisons.

Scopus Biopharma's long-term debt changed from $0 to $0 (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Scopus Biopharma reported $0 in long-term debt as of June 2023. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Scopus Biopharma, and consider following SCPS for alerts when major investors trade the stock.

Scopus Biopharma is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SCPS with unrelated industries.